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Abstract
Background: Pneumonia patients with wheezing due to influenza A(H1N1)pdm09 were frequently treated with systemic
corticosteroids in Japan although systemic corticosteroid for critically ill patients with pneumonia caused by influenza
A(H1N1)pdm09 has been controversial. Applicability of systemic corticosteroid treatment needs to be evaluated.
Methods/Principal Findings: We retrospectively reviewed 89 subjects who were diagnosed with influenza A(H1N1)pdm09
and admitted to a national hospital, Tokyo during the pandemic period. The median age of subjects (45 males) was 8 years
(range, 0–71). All subjects were treated with antiviral agents and the median time from symptom onset to initiation of
antiviral agents was 2 days (range, 0–7). Subjects were classified into four groups: upper respiratory tract infection,
wheezing illness, pneumonia with wheezing, and pneumonia without wheezing. The characteristics of each group was
evaluated. A history of asthma was found more frequently in the wheezing illness (55.6%) and pneumonia with wheezing
(43.3%) groups than in the other two groups (p=0.017). Corticosteroid treatment was assessed among subjects with
pneumonia. Oxygen saturation was lower in subjects receiving corticosteroids (steroid group) than in subjects not receiving
corticosteroids (no-steroid group) (p,0.001). The steroid group required greater oxygen supply than the no-steroid group
(p,0.001). No significant difference was found by the Kaplan-Meier method between the steroid and the no-steroid groups
in hours to fever alleviation from the initiation of antiviral agents and hospitalization days. In logistic regression analysis,
wheezing, pneumonia and oxygen saturation were independent factors associated with using systemic corticosteroids.
Conclusion: Patients with wheezing and a history of asthma were frequently found in the study subjects. Systemic
corticosteroids together with early administration of antiviral agents to pneumonia with wheezing and possibly without
wheezing did not result in negative clinical outcomes and may prevent progression to severe pneumonia in this study
population.
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Introduction
Although systemic corticosteroid treatment for severe pneumonia
due to influenza A(H1N1)pdm09 has been controversial [1,2,3],
systemic corticosteroid treatment in pneumonia patients especially
presenting with acute wheezing induced by influenza A(H1N1)pdm09
was frequently administered at the early stage of their illness in hospitals
in Japan during pandemic period. Wheezing is the end result of a
narrowing of the intrathoracic airways and a limitation of expiratory
air flow and is caused by many illnesses. Asthma and bronchiolitis were
the main illnesses which caused wheezing in influenza A(H1N1)pdm09
virus infection [4,5,6,7,8]. Acute exacerbation of asthma is usually
diagnosed in patients with wheezing and a history of asthma. It is
treated with anti-asthma agents as well as systematic corticosteroids
depending on the disease severity following the asthma treatment
guidelines [9,10,11]. On the other hand, a previous study in preschool
children with acute virus-induced wheezing indicated that systemic
corticosteroid treatment was not superior to placebo [12]. Also, a study
in infants with bronchiolitis concluded that treatment with systemic
corticosteroid did not significantly affect hospitalization [13]. It has
been physicians’ questions whether pneumonia patients presenting
with wheezing need to be treated with systemic corticosteroid during
the pandemic period.
The aim of the present study was to evaluate if systemic
corticosteroid treatment is suitable for hospitalized pneumonia
patients with acute wheezing caused by influenza A(H1N1)pdm09.
Materials and Methods
Study design
We retrospectively reviewed the clinical data, chest radiologic
and laboratory findings of all hospitalized patients diagnosed with
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2009 and March 2010 to the National Center for Global Health
and Medicine (NCGM), which is a tertiary care hospital in Tokyo,
Japan. Influenza A(H1N1)pdm09 infection was diagnosed accord-
ing to case definitions developed by the World Health Organiza-
tion [14]. Respiratory tract specimens of patients were either
tested positive for the influenza A(H1N1)pdm09 virus by real-time
reverse-transcriptase-polymerase-chain-reaction (RT-PCR) or test-
ed positive for influenza A virus by ImunoAce FluH (TAUNS
Laboratories, Inc.) or EsplineH (Fujirebio Inc.), rapid diagnosis
tests using an immunochromatography assay, which are approved
by the Ministry of Health, Welfare, and Labour, Japan. Among all
hospitalized patients, subjects who presented with respiratory
disorders were eligible as study subjects and classified into four
groups based on their respiratory disorders: upper respiratory tract
infection, wheezing illness, pneumonia with wheezing, and
pneumonia without wheezing (Figure 1). The four groups were
compared and evaluated in terms of the relationships among
clinical conditions, clinical time course, and treatments. The
clinical effects for systemic corticosteroids treatment were
evaluated among the subjects with pneumonia. Also, clinical
factors which leaded to prescribe systemic corticosteroids were
assessed among the study subjects. Systemic corticosteroid was
administered based on the treatment for acute exacerbation of
asthma in the asthma guidelines [9,10,11]. Wheezing was defined
as a continuous high pitched sound emitting from the chest during
expiration on auscultation. Pneumonia was diagnosed on the basis
of infiltrative shadows on chest radiograph.
Statistical analysis
Subjects’ background data and clinical laboratory values were
summarized and compared among groups of respiratory disorders
as well as between those who did (steroid group) and did not (no-
steroid group) receive systemic corticosteroid treatment. The
Mann-Whitney test and Kruskal-Wallis test were used for
continuous variables, and the Chi-square test and Fisher’s exact
test were used for categorical variables. Survival curves on the
numbers of hours to fever alleviation from initiation of
administration of antiviral agents and the duration of hospitaliza-
tion in the steroid and the no-steroid groups were analyzed by the
Kaplan-Meier method and comparisons were made using the log-
rank test. For the evaluation of independent factors for using
systemic corticosteroid treatment, a step-wise selection method was
used to select significant factors if p,0.1 in the univariate analysis
for a logistic regression analysis. Data analyses were conducted
using SPSS statistics ver.19 (IBM, Armonk, NY, USA). For all
analyses, significance levels were two tailed, and a p value of
,0.05 was considered significant.
Ethics statement
The study was approved by the Institutional Review Board of
the NCGM. Informed consent was waived by the Board for this
retrospective study, with the study notification to public being
made by posters. Investigators kept the datasets in password-
protected systems and presented data with the anonymity of study
patients retained.
Results
Characteristics of the study subjects
During the study period, a total 104 patients were diagnosed
with influenza A(H1N1)pdm09 and admitted to the NCGM.
Among them, 89 (85.6%) patients who presented with respiratory
disorders were eligible as study subjects (Figure 1). Some subjects
were admitted with reasons other than respiratory disorders
including encephalopathy, dehydration, and abdominal symptoms
due to influenza infection.
The number of subjects in each category of respiratory disorders
was as follows: upper respiratory tract infection (n=22, 24.7%);
wheezing illness (n=9, 10.1%); pneumonia with wheezing (n=30,
33.7%); and pneumonia without wheezing (n=28, 31.5%). Of all
89 subjects,the numberof subjectswithpneumoniawas58 (65.2%).
The characteristics of subjects according to respiratory disorders
are shown in Table 1. The median age of study subjects (45 male)
was 8 years (range, 0–71), and 80 subjects (89.9%) were aged less
than 15 years. More subjects with wheezing illness (55.6%) or
pneumonia with wheezing (43.3%) had a history of asthma than
did those with upper respiratory tract infection (13.6%) or
pneumonia without wheezing (17.9%), and there were significant
differences among the groups (p=0.017). The median oxygen
saturation (SpO2) in room air on admission in subjects with
wheezing illness (91.0%) or pneumonia with wheezing (90.0%)
were lower than those in subjects with upper respiratory tract
infection (96.5%) or pneumonia without wheezing (93.0%), and
there were significant differences among the groups (p,0.001).
Bacterial co-infection was detected in throat swabs and/or sputum
in 44.9% of subjects, but there was no significant difference among
the groups. In terms of laboratory findings, including total serum
Immunoglobulin E level, there were no significant differences
among the groups.
Treatment and clinical time course of study subjects
The treatments and clinical time courses of study subjects in
each classified group of respiratory disorders during hospitalization
are shown in Table 2.
All subjects were treated with antiviral agents, either oseltamivir
or zanamivir. In some subjects antiviral medication was switched
from oseltamivir to zanamivir or vice versa. The regular dose of
oseltamivir was 150 mg/day for 5 days in adults, and 4 mg/kg/
day for 5 days in pediatric patients. The regular dose of zanamivir
was 20 mg/day for 5 days. The median number of days from
symptom onset to initiation of administration of antiviral agents
was 1.9 (range, 1–7), and the length to antiviral treatment from the
symptom onset in the pneumonia with wheezing group tended to
be longer (2.4 days; range, 1–5) (p=0.054).
Systemic corticosteroid was used in 93.3% of pneumonia with
wheezing subjects, 77.8% of wheezing illness subjects, and 64.3%
of pneumonia without wheezing subjects (p,0.001). The dosage of
corticosteroids was equivalent to methylprednisolone 1.0–1.5 mg/
body weight (kg)/time, 2–4 times/day, in subjects under 15 years
of age, and 40–80 mg/time, 2–4 times/day in those over 15 years
of age. The median number of days from symptom onset to
initiation of administration of systemic corticosteroids was 2.1
(range, 1–6), The median duration of systemic corticosteroid
treatment was 5.2 days (range, 2–9).
Treatment with anti-asthmatic agents other than corticosteroids
were included in drug regimens for asthmatic episodes, cough and
sputum using at least one of the following: short-acting b2-agonist,
long-acting b2-agonist, inhaled isoproterenol, inhaled disodium
cromoglycate, aminophylline, and leukotriene receptor antagonist.
All subjects in wheezing illness and pneumonia with wheezing
groups received anti-asthma treatments; also, 27.3% of those with
respiratory tract infections and 75.0% of those with pneumonia
without wheezing had at least one administration with anti-asthma
agent (p,0.001).
Oxygen was administered using a nasal cannula or face mask to
56.2% of subjects with respiratory disorders, but no subjects
required mechanical ventilation.
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tion of antiviral agents was not significantly different among the
groups (p=0.967). There was a longer duration of hospitalization
in the pneumonia groups with and without wheezing compared
with the other two groups, and there was significant difference
among the groups (p,0.001).
Evaluation of systemic corticosteroid treatment among
subjects with pneumonia
Systemic corticosteroid treatment was evaluated in subjects with
pneumonia (n=58) and compared between subjects in the steroid
group and in the no-steroid group (Table 3).
Wheezing was presented 58.7% in the steroid group and there
was a significant difference between the groups (p=0.002). SpO2 in
the steroid group was lower than that in the no-steroid group
(SpO2,90.0%vs.95.6,respectively;p,0.001)and the steroidgroup
required more oxygen supply than the no-steroid group (97.8% vs.
8.3%, respectively; p,0.001). Anti-asthma treatment was applied to
97.8% of the steroid group and 50.0% of the no-steroid group
(p,0.001). Although bacterial co-infection was found in 52.2% of
the steroid group and 25.0% of the no-steroid group at the time of
admission (p=0.093), antibiotics were administered to both the
steroid and the no-steroid groups (89.1% vs. 50.0%, respectively;
p=0.006). There were no significant differences in terms of time to
feveralleviation(,37uC)afteradministrationofantiviralagentsand
in the duration of hospitalization between the groups (p=0.611 and
0.599, respectively).
Clinical time course were assessed by the Kaplan-Meier method
on time to fever alleviation from the initiation of administration of
antiviral agents and duration of hospitalization in subjects with
pneumonia (n=58) and compared between the steroid and the no-
steroid groups using the log-rank test (Figure 2). There were no
significant differences between the groups in both time to fever
alleviation (p=0.835) and the duration of hospitalization
(p=0.626).
Clinical factors for using systemic corticosteroids
treatment among the study subjects
A multiple logistic regression analysis using baseline factors was
conducted for subjects with respiratory disorders (n=89).
Wheezing, pneumonia and SpO2 on admission were independent
clinical factors associated with using systemic corticosteroids
treatment (Table 4).
Discussion
Our evaluation of hospitalized patients with pneumonia caused
by influenza A(H1N1)pdm09, who were mostly young and
Figure 1. Study population. A total of 104 patients were diagnosed with pandemic influenza A(H1N1)pdm09. Five patients (one of whom died)
were admitted to the ICU and were excluded from the study. The remaining 99 patients were the study subjects. Among them, 89 subjects presented
with respiratory disorders and 10 presented with symptoms other than respiratory disorders, including encephalopathy. The subjects with respiratory
disorders were classified into the following four groups: upper respiratory tract infection (n=22), wheezing illness (n=9), pneumonia with wheezing
(n=30), and pneumonia without wheezing (n=28). The total number of subjects with pneumonia was 58.
doi:10.1371/journal.pone.0032280.g001
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roid treatment did not result in negative clinical outcomes if
patients were treated with antiviral agents during the early stage of
illness.
Although asthma is not the only illness that causes wheezing, asthma
is a risk comorbidity for influenza A(H1N1)pdm09 [8]. In the present
study, wheezing was observed in 43.8% of all subjects, including in
subjects who presented with pneumonia (Table 1). Systemic
corticosteroid treatment is recommended in the asthma guidelines
for treating acute exacerbation of asthma which requires hospitaliza-
tion [9,10,11], but its use remains uncertain for asthma-exacerbated
patients with pneumonia due to influenza A(H1N1)pdm09 [1,2,3].
The healthcare seeking behavior for people in Japan is
customarily early especially for acute diseases including pandemic
influenza and a median days to the initiation of treatment with
antiviral agents from the symptom onset was 1.9 days (range, 1–7)
in the study subjects (Table 2). The previous study in Mexico
reported that the earlier administration of antiviral agent reduced
severity of pneumonia, occurrence of pneumonia, and the
duration of hospitalization [15]. In the present study, the study
subjects were not admitted in the ICU, did not require mechanical
ventilation support, and the median of duration of hospitalization
was 7 days (range, 2–14) (Table 1). These results indicated that the
study subjects, who were mostly young and were initiated the
Table 1. Background and clinical characteristics of study subjects.
Upper respiratory tract
infection
Wheezing*
illness
Pneumonia
{ with
wheezing
Pneumonia without
wheezing Total P value
Number of patients (%) 22 (24.7) 9 (10.1) 30 (33.7) 28 (31.5) 89 (100.0) 0.007
Gender, male (%) 10 (45.5) 9 (100.0) 17 (56.7) 9 (32.1) 45 (50.6) 0.004
Age-yr. 0.143
,15 18 (81.8) 8 (88.9) 30 (100.0) 24 (85.7) 80 (89.9)
$15 4 (18.2) 1 (11.1) 0 (0.0) 4 (14.3) 9 (10.1)
Vaccination
Seasonal influenza vaccine of
2009–2011
3 (13.6) 2 (22.2) 7 (23.3) 5 (17.9) 17 (19.1) 0.956
Influenza A(H1N1) pdm09 vaccine 0 (0.0) 5 (27.8) 3 (16.7) 2 (33.3) 10 (18.5) 0.145
Comorbidity
Asthma
{ 3 (13.6) 5 (55.6) 13 (43.3) 5 (17.9) 26 (29.2) 0.017
Others
1 1 (4.5) 1 (11.1) 0 (0.0) 1 (3.6) 3 (3.4) 0.236
Family asthma history 4 (18.2) 3 (33.3) 13 (43.3) 5 (17.9) 25 (28.1) 0.107
Physical findings
Body temperature uC, median (range) 38.5 (35.9–40.4) 38.6 (37.2–38.8) 38.6 (36.5–40.3) 38.6 (36.2–40.2) 38.6 (35.9–40.4) 0.729
SpO2
" -%, median (tange) 96.5 (87–98) 91.0 (86–97) 90.0 (82–97) 93.0 (74–98) 92.0 (74–98) ,0.001
Co-infection
I - No. (%) 6 (27.3) 7 (77.8) 14 (46.7) 13 (46.4) 40 (44.9) 0.081
Laboratory findings – median
(range)
WBC (10
3/mL) 6730 (3260–13980) 15810 (6100–
13450)
8000 (2790–16280) 6820 (900–15580) 7740 (900–16280) 0.056
Hemoglobin (g/dL) 13.3 (10.2–16.8) 13.2 (12.0–17.5) 13.4 (4.9–14.9) 13.4 (10.7–15.6) 13.4 (4.9–17.5) 0.911
Platelet (10
3/mL) 20.3 (8–39) 26.6 (17–44) 23.8 (14–193) 23.2 (12–135) 22.9 (8–193) 0.103
LDH (U/L) 240.5 (168–407) 287.0 (239–397) 270.5 (218–418) 264.5 (183–438) 265.0 (168–438) 0.057
ALP (U/L) 513.5 (7–1173) 748 (240–1091) 620 (449–1008) 603 (123–756) 614.0 (7–1173) 0.224
AST (U/L) 28.0 (16–79) 31.0 (25–50) 29.0 (19–45) 27.0 (21–100) 29.0 (16–100) 0.235
ALT (U/L) 15.0 (8–33) 18.0 (14–33) 13.5 (10–34) 14.5 (8–70) 15.0 (8–70) 0.016
Creatinine (mg/dL) 0.44 (0.22–1.01) 0.3 (0.21–1.03) 0.35 (0.18–0.91) 0.41 (0.26–2.69) 0.40 (0.18–2.69) 0.087
Sodium (mEq/L) 135.0 (129–141) 136 (133–138) 135 (130–141) 135.5 (126–140) 135.0 (126–141) 0.364
Potassium (mEq/L) 3.9 (3.4–5.2) 4.1 (3.5–5.0) 4.0 (3.4–4.6) 4.0 83.3–4.4) 4.0 (3.3–5.2) 0.698
CRP (mg/dL) 0.91 (0–11) 0.83 (0.19–2.06) 1.91 (0.05–9.23) 1.0 (0.07–10.41) 1.17 0.0–11.04) 0.271
Total serum IgE (U/mL) 101.0 (21–6691) 74.0 (3–382) 473.5 (1–9179) 283.0 (25–3440) 243.0 (1–9179) 0.164
*Wheezing was defined as a continuous high pitched sound emitting from the chest during expiration on auscultation.
{Pneumonia was diagnosed on the basis of infiltrative shadows on chest radiograph.
{Asthma includes active asthma and inactive asthma.
1Other comorbidities include smoking , alcoholism, diabetis meritis, chronic heart diseases , obesity.
"SpO2: oxygen saturation measured by pulse oximetry in room air.
IPathogenic bacteria co-infection was detected by throat swabs and/or sputum.
Definition of abbreviations: WBC, white blood cell count; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; AST, aspartate amino transferase; ALT, alanine
aminotransferase; CRP, C-reactive protein; IgE, Immunoglobulin E.
doi:10.1371/journal.pone.0032280.t001
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critical.
Most subjects presented with respiratory disorders, including
upper respiratory tract infection, wheezing illness, and pneumonia
with or without wheezing. Wheezing is one of the manifestations of
asthma and a previous report indicated that wheezing is associated
with influenza mortality [16]. In the present study, total 43.8% of
subjects presented wheezing and 33.7% presented both pneumo-
nia and wheezing. Also, asthma history was more frequent among
subjects with wheezing illness (55.6%) or pneumonia with
wheezing (43.3%) than among the other subjects in upper
respiratory infection (13.6%) and pneumonia without wheezing
(17.9%) (Table 1). The results indicated that the occurrence of
exacerbation of asthma might have been increased by influenza
A(H1N1)pdm09 in this study population; however, exacerbation
of asthma did not became critical. Systemic corticosteroid was
mainly used for patients with wheezing either with pneumonia or
without pneumonia. The presentation of wheezing can lead to a
diagnosis of asthma if the patients have a history of asthma. Also,
wheezing could also indicate a first episode of asthma attack or
bronchiolitis, which are difficult to distinguish on the basis of
wheezing alone. If a patient has asthma acute exacerbation or a
first episode of asthma attack, not using systemic corticosteroids
can increase disease severity and mortality [9,10,11]. Therefore,
systemic corticosteroid treatment should be a consideration for
clinical management of patients with wheezing despite the
presence of viral pneumonia and/or bronchiolitis. Also, anti-
asthmatic agents other than systemic corticosteroids were
administered to all subjects with wheezing (Table 2). Treatments
with anti-asthmatic agents together with corticosteroids need to be
included as well as antibiotic agents in case of bacterial co-
infection.
Respiratory condition, as reflected by SpO2, was more severe in
subjects of the steroid group than in the non-steroid group
(Table 3). Also, oxygen was more supplied to the steroid group.
Those results described that respiratory condition was more severe
in the steroid group; however, systemic corticosteroid treatment
has no influence to hours to fever alleviation after the initiation of
treatment with antiviral agents and the duration of hospitalization
(Table 3). In terms of assessment of clinical time course, the
Kaplan-Meier curves for hours to fever alleviation from the
initiation of antiviral agents and hospitalization days were not
significantly different between the steroid and the non-steroid
groups. (Figure 2). Systemic corticosteroids were administered for
the most of subjects with wheezing (Table 2). These results suggests
that systemic corticosteroid treatment for viral pneumonia with
wheezing may not have negative effects to clinical time course.
Multiple logistic regression analysis among subjects with
respiratory disorders evaluated that wheezing, pneumonia, and
SpO2 were independent factors associated with using systemic
corticosteroid treatment (Table 4). The results indicated that these
were factors that could motivate physicians to start systemic
Table 2. Treatment and clinical time course of study subjects.
Upper respiratory
tract infection
Wheezing*
illness
Pneumonia
{" with
wheezing
Pneumonia without
wheezing Total P value
Number of subjects (%) 22 (24.7) 9 (10.1) 30 (33.7) 28 (31.5) 89 (100.0) 0.007
Treatments
Time to initiation of antiviral agents from symptom
onset - median days (range)
1.8 (1–3) 1.7 (1–3) 2.4 (1–5) 1.6 (1–7) 1.9 (1–7) 0.054
Antiviral agents 0.006
Oseltamivir 12 (54.5) 7 (77.8) 22 (73.3) 12 (42.9) 53 (59.6)
Zanamivir 9 (40.9) 2 (22.2) 7 (23.3) 13 (46.4) 31 (34.8)
Both oseltamivir and zanamivir
{ 1 (4.5) 0 (0.0) 1 (3.3) 3 (10.7) 5 (5.6)
Systemic corticosteroid treatment
1 4 (18.2) 7 (77.8) 28 (93.3) 18 (64.3) 57 (64.0) ,0.001
Time to initiation of systemic corticosteroids from
symptom onset - median days (range)
2.0 (2–2) 2.0 (1–5) 2.4 (1–6) 1.8 (1–5) 2.1 (1–6) 0.134
Duration of systemic corticosteroid treatment-
median days (range)
5.0 (4–6) 3.3 (2–6) 5.8 (3–9) 4.4 (2–8) 5.2 (2–9) ,0.001
Anti-asthma agents other than corticosteroid
" 6 (27.3) 9 (100.0) 30 (100.0) 21 (75.0) 66 (74.2) ,0.001
Oxygen supply
I 7 (31.8) 5 (55.6) 19 (63.3) 19 (67.9) 50 (56.2) 0.002
Antibiotics** 8 (36.4) 8 (88.9) 28 (93.3) 19 (67.9) 63 (70.8) ,0.001
Clinical time course
Time to fever alleviation* - hours, median (range) 35.4(11–120) 44.0 (14–116) 32.0 (12–150) 37.3 (9–168) 35.0 (9–
168)
0.967
Length of Hospitalization, days, median (range) 4.9 (2–9) 6.8 (3–10) 8.4 (6–14) 7.6 (3–14) 7.5 (2–14) ,0.001
*Wheezing was defined as a continuous high pitched sound emitting from the chest during expiration on auscultation.
{Pneumonia was diagnosed on the basis of infiltrative shadows on chest radiograph.
{Antiviral medication was switched oseltamivir to zanamivire and vice versa.
1The dose of corticosteroid was equivalent to methylprednisolone 1.0–1.5 mg/body weight (kg)/time, 2–4 times/day, in subjects under 15 years of age, and 40–80 mg/
time, 2–4 times/day in those over 15 years of age.
"At least one medication of shortacting b2-agonist, longacting b2-agonist, inhaled isoproterenol, inhaled disodium cromoglycate, aminophylline, and leukotriene
receptor antagonists.
IOxygen was administered using a nasal cannula or face mask.
**Antibiotics.
doi:10.1371/journal.pone.0032280.t002
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wheezing was not the only factor for using systemic corticosteroid
treatment but also pneumonia and low level of respiratory
condition which were reflected by SpO2. In the present study,
systemic corticosteroid treatment did not produce negative
outcomes, even in patients with pneumonia and might be in
patients with bronchiolitis. The results showed that the systemic
corticosteroid treatment in the early stage of illness together with
antiviral agents might work to reduce the time of critical
conditions and to prevent disease progression to severe pneumonia
among patients who were administered antiviral agents during the
early stage of illness when their pneumonia were not so severe
(Table 2).
Although secondary bacterial infection was reported as a
negative outcome of systemic corticosteroid treatment in the
severe ill patients with influenza H1N1pdm09 [2], in the present
study, no significant effects of systemic corticosteroid treatment
against bacterial co-infection were observed. It might be resulted
from the antibiotics treatment from the hospital admission
(Table 2, 3) and can be explained by the short duration of
hospitalization of study subjects. (Table 2, 3).
Limitations of the present retrospective study are that the
influenza HN1 2009 virus was confirmed in the limited number
of subjects by RT-PCR and patients strongly considered to have
2009 influenza A/H1N1 virus infection were included. During
the study period, influenza A(H1N1)pdm09 virus was the
dominant influenza virus in Japan according to the Infectious
Agent Surveillance Report in Japan [17]. Subjects who were
identified as having influenza A virus infection were strongly
considered to have influenza A(H1N1)pdm09 virus infection, so
physicians diagnosed those patients as having influenza
A(H1N1)pdm09 infection. Also, most of the study subjects were
pediatric patients and the age distribution of the study subjects
was representative of that for influenza A(H1N1)pdm09 in Japan
[17,18]. The number of subjects in divided four groups according
to the respiratory conditions were not equal as well as the small
number of subjects without steroids treatment due to the
retrospective study in a single hospital. Therefore, the further
prospective study in patients with a variety of ages with large
population is needed.
In conclusions, systemic corticosteroid treatment together with
early administration of antiviral agents did not result in negative
clinical outcomes in patients with influenza viral pneumonia with
wheezing and without wheezing in the present study. The findings
suggest that influenza pneumonia patients with wheezing and
potentially without wheezing could be treated by systemic
corticosteroids and early administration of antiviral agents if the
severity of disease is before critical condition.
Table 3. Clinical presentation of subjects with pneumonia according to systemic corticosteroid treatment.
Steroid group* No-steroid group* Total P value
Number of subjects No. (%) 46 (100) 12 (100) 58 (100)
Symptoms and signs on admission
Wheezing
{ -No. (%) 27 (58.7) 1 (8.3) 28 (48.3) 0.002
Co-infection
{-No. (%) 24 (52.2) 3 (25.0) 27 (46.6) 0.093
Body temperature -uC, median (range) 38.6 (36.5–40.3) 38.2 (36.2–40.2) 38.6 (36.2–40.3) 0.261
Laboratory findings on admission, median (range)
SpO2
1 (%) 90.0 (74–97) 95.6 (91–98) 91.0 (74–98) ,0.001
WBC (10
3/mL) 8200 (2790–16280) 6385.0 (900–13280) 7715.0 (900–16280) 0.024
LDH (U/L) 270 (201–418) 255.5 (183–438) 267.5 (183–438) 0.687
CRP (mg/dL) 1.16 (0.05–9.23) 2.69 (0.07–10.41) 1.22 (0.05–10.41) 0.154
Sodium (mEq/L) 135.1 (130–141) 134.8 (126–139) 135 (126–141) 0.734
Potassium (mEq/L) 3.96 (3.3–4.6) 3.39 (3.3–4.5) 3.95 (3.3–4.6) 0.438
Treatment -No. (%)
Days to administration of antiviral agents
" 2.0 (1–5) 1.8 (1–7) 2.0 (1–7) 0.589
Anti-asthma treatments
I 45 (97.8) 6 (50.0) 51 (87.9) ,0.001
Antibiotic agents 41 (89.1) 6 (50.0) 47 (81.0) 0.006
Oxygen supply** 45 (97.8) 1 (8.3) 46 (79.3) ,0.001
Clinical outcomes, median (range)
Hours to alleviation of fever after admission
{{ 36.0 (9–150) 35.5 (9–168) 35.5 (9–168) 0.611
Hospitalization days 8.2 (5–14) 7.7(3–14) 8.1 (3–14) 0.607
N=58.
*No-steroid and steroid group denote group of subjects who were not treated and treated with systematic corticosteroids.
{Wheezing was defined as a continuous high pitched sound emitting from the chest during expiration on auscultation.
{Pathogenic bacteria co-infection was detected by throat swabs and/or sputum.
1SpO2: oxygen saturation measured by pulse oximetry in room air.
"The number of days from symptom onset to the initiation of administration of antiviral agent either oseltamivir or zanamivir.
IAt least one medication of short-acting b2-agonist, long-acting b2-agonist, inhaled isoproterenol, inhaled disodium cromoglycate, aminophylline, and leukotriene
receptor antagonists.
**Oxygen was administered using a nasal cannula or face mask.
{{The time (hours) to alleviation of fever to less than 37uC after the administration of antiviral agents.
Definition of abbreviation: WBC, white blood cell count; LDH, lactate dehydrogenase; CRP, C-reactive protein.
doi:10.1371/journal.pone.0032280.t003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32280Figure 2. Systemic corticosteroids treatment in the relation0 to clinical time course assessed by Kaplan-Meier methods. Kaplan-Meier
curves of the number of hours to fever alleviation (A) and hospitalization days (B) according to systemic corticosteroid treatment among subjects
with viral pneumonia in steroid (n=46) and non-steroid (n=12) groups There were no significant differences between the groups in terms of either
hours to fever alleviation (log rank test, p=0.835) or hospitalization days (log rank test, p=0.626).
doi:10.1371/journal.pone.0032280.g002
Steroids in Influenza Pneumonia with Wheezing
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32280Acknowledgments
The authors thank Kaori Okuma, Yoshiyuki Okuma, Junko Yamanaka,
Noriko Sato, Takayuki Jodai, Jun Sugihara and Shinyu Izumi for assisting
with the study.
Author Contributions
Conceived and designed the experiments: KK. Performed the experiments:
KK JT HU RY TM EK NK TJM. Analyzed the data: TM KK. Wrote the
paper: KK TM.
References
1. Brun-Buisson C, Richard JC, Mercat A, Tiebaut AC, Brochard L, for the
REVA-SRLF A/H1N1 v 2009 Registry Group (2011) Early Corticosteroids in
Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress
Syndrome. Am J Respir Care Med 183(9): 1200–6.
2. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, et al. (2011) Corticosteroid
Treatment in Critically Ill Patients with Pandemic Influenza A/H1N1 2009
Infection: Analytic Strategy Using Propensity Scores. Am J Respir Care Med
183(9): 1207–14.
3. Hong-Ryang K, Jae-Ho L, Kyung-Yil L, Jung-Woo R, You-Sook Y, et al. (2011)
Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1
influenza virus. Critical Care 15: 413.
4. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M,
Quin ˜ones-Falconi F, et al. (2009) Pneumonia and respiratory failure from swine-
origin influenza A (H1N1) in Mexico. N Engl J Med 361: 680–689.
5. Jaian S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, et al. (2009)
Hospitalized patients with 2009 H1N1 influenza in the United States, April–
June 2009. N Engl J Med 302: 1896–1902.
6. The ANZIC Influenza Investigators, Webb SA, Aubron C, Bailey M, Bellomo R,
et al. (2009) Critical care services and 2009 H1N1 influenza in Australia and
New Zealand. N Engl J Med 361: 1925–1934.
7. Louie JK, Acosta M, Jean C, Gavali S, Schechter R, et al. (2009) Factors
Associated With Death or Hospitalization Due to Pandemic 2009 Influenza
A(H1N1) Infection in California. JAMA 302: 1896–1902.
8. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic
(H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA,
Shaw M, et al. (2010) Clinical aspects of Pandemic 2009 Influenza A (H1N1)
virus infection. N Engl J Med 362: 1708–1719.
9. The Global Initiative for Asthma(GINA) (2010) Global Strategy for Asthma
Management and Prevention. Available: http://www.ginasthma.org/pdf/G
INA_Report_2010.pdf. Accessed 2011 September 10.
10. National Asthma Education and Prevention Program (2007) Guidelines for the
Diagnosis and Management of Asthma, Expert Panel ReportIII. Bethesda:
National Heart, Lung and Blood Institute, NHI.
11. Japanese Society of Allergoology (2009) Asthma Prevention and Management
Guidelines 2009, Japan. Tokyo: Kyowa Kikaku Press. pp 113–139. (in
Japanese).
12. Panickar J, Lakhanpaul M, Lambert PC, Kenia P, Stephenson T, et al. (2009)
Oral Prednosolone for Preschool Children with Acute Virus-Induced Wheezing.
N Engl J Med 360: 329–38.
13. Corneli H, Zorc JJ, Mahjan P, Shaw KN, Holubkov R, et al. (2007) A
Multicenter, Randomized, Controlled Trial of Dexamethasone for Bronchiolitis.
N Engl J Med 357: 331–9.
14. World Health Organization (2010) WHO guidelines for pharmacological
management of pandemic (H1N1) 2009 influenza and other influenza viruses.
Available: http://www.who.int/csr/resources/publications/swineflu/h1n1_gui-
delines_pharmaceutical_mngt.pdf. Accessed 2010 September 1.
15. Higuera Iglesias AL, Kudo K, Manabe T, Corcho Berdugo AE, Baeza AC, et al.
(2011) Reducing Occurrence and Severity of Pneumonia Due to Pandemic
H1N1 2009 by Early Oseltamivir Administration: A Retrospective Study in
Mexico. PLoS ONE 6(7): e21838 p. doi:10.1371/journal.pone.0021838.
16. Riquelme R, Jimenez P, Videla AJ, Lopez H, Chalmers J, et al. (2010) Predicting
morality in hospitalized patients with 2009 H1N1 influenza pneumonia.
Int J Tuberc Lung Dis 15(4): 542–546.
17. Infectious Disease Surveillance Center (2009) Pandemic influenza A(H1N1)
situation report of Japan, update 27. Available: http://idsc.nih.go.jp/disease/
swine_influenza_e/idsc_e2009/09idsc27e.html. Accessed 2011 August.
18. The Ministry of Health, Labour, and Welfare (2011) The trend of pandemic
H1N1 2009: Epidemiological information for medical providers ver. 3.
Available: http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/
pdf/100423-01.pdf. (in Japanese). Accessed 2011 August.
Table 4. Clinical factors for using systemic corticosteroids treatment among the study subjects by multiple logistic regression
analysis.
Parameter Regression coefficient Standard error P value Odds ratio 95% confidence interval
Intercept 20.444 8.927
Wheezing* 2.401 0.841 0.004 11.03 2.12–57.33
Pneumonia
{ 1.298 0.618 0.036 3.66 1.09–12.30
SpO2
{ 20.229 0.094 0.015 0.80 0.66–0.96
n=89.
*Wheezing was defined as a continuous high pitched sound emitting from the chest during expiration on auscultation.
{Pneumonia was diagnosed on the basis of infiltrative shadows on chest radiograph.
{SpO2: oxygen saturation measured by pulse oximetry in room air on admission.
doi:10.1371/journal.pone.0032280.t004
Steroids in Influenza Pneumonia with Wheezing
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32280